Document is current
Any future updates will be listed below
-
Authors
Barriga, Francisco M. http://orcid.org/0000-0002-0996-7707
Tsanov, Kaloyan M.
Ho, Yu-Jui
Sohail, Noor
Zhang, Amy
Baslan, Timour
Wuest, Alexandra N.
Del Priore, Isabella
Meškauskaitė, Brigita
Livshits, Geulah
Alonso-Curbelo, Direna
Simon, Janelle
Chaves-Perez, Almudena
Bar-Sagi, Dafna
Iacobuzio-Donahue, Christine A. http://orcid.org/0000-0002-4672-3023
Notta, Faiyaz
Chaligne, Ronan http://orcid.org/0000-0003-4332-3291
Sharma, Roshan
Pe’er, Dana http://orcid.org/0000-0002-9259-8817
Lowe, Scott W. http://orcid.org/0000-0002-5284-9650
- License Information
-
More Information
Article History
Received: 10 August 2022
Accepted: 13 September 2022
First Online: 7 November 2022
Competing interests
: S.W.L. is a consultant and holds equity in Blueprint Medicines, ORIC Pharmaceuticals, Mirimus, PMV Pharmaceuticals, Faeth Therapeutics, Senescea Therapeutics, and Constellation Pharmaceuticals. All other authors have no competing interests.
